$LAZ

LAZ Maintained by Goldman Sachs -- Price Target Lowered to $32.0

Goldman Sachs lowered its price target for Lazard (LAZ) to $32.00 from $36.00, maintaining a 'Sell' rating. The firm's GF Value™ is $46.52, suggesting a 20.4% undervaluation, while its GF Score™ is 83/100. Insiders sold $5.44M in shares over the last 3 months. Lazard has a market cap of $3.61B and operates in financial advisory and asset management.

Original reporting
Published Oct 13, 2026, 11:32 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 12:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$LAZ
Bearish
high confidence
Mentioned
$LAZ
Relevance
5/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$LAZBearishMed
01

Why it matters

A lowered price target with a maintained Sell rating is a sentiment and positioning catalyst, but the article does not introduce new company fundamentals (no earnings/guidance print).

02

Market read

Traders may adjust short-term expectations for LAZ based on the new target cut, but conviction is tempered by the lack of fresh operating data in the article.

03

What to watch

The piece leans on analyst caution and insider selling, but it does not provide new quarterly results, guidance, or a specific operational trigger that would force a fundamental repricing.

Relevance 5/10Novelty 5/10Timing: today, as the analyst price-target cut is newly reported

Background

The article is an analyst-rating update from Goldman Sachs, framed by GuruFocus metrics (GF Value, GF Score) and recent insider selling.

Company-level read

Ticker impact

$LAZBearishHigh confidence
Context

Goldman Sachs maintained a Sell on Lazard and cut its price target to $32 from $36, citing a cautious outlook on growth and profitability.

Expected impact

Likely downward bias as the market reprices Lazard’s near-term earnings and profitability expectations around the lowered target.

Evidence & confidence

The article’s only company-specific catalyst is the Sell rating maintenance plus a concrete price-target reduction, which typically weighs on sentiment and near-term positioning.

Market effects

Adds to capital-markets advisory caution, reinforcing a risk-off tone for fee-based financial services when growth/profitability are questioned.

Primarily US-listed sentiment for financials, with limited direct spillover beyond sell-side positioning.

Low, as the catalyst is a single-company analyst action rather than a cross-market macro or regulatory development.

Counterpoint

The article also cites a higher intrinsic-value estimate (GF Value) and a dividend yield, which could attract value and income buyers despite the Sell rating.

Key entities

  • Lazard Inc.

    Subject of the analyst rating update, with Goldman Sachs maintaining a Sell and lowering the price target to $32.

  • Goldman Sachs

    Issued the rating maintenance and price-target reduction referenced in the article.

Related articles

$LAZMed

Citizens reiterates Lazard stock rating citing strong forward indicators

Citizens maintained its Market Outperform rating and $60.00 price target on Lazard (NYSE:LAZ) after its Q3 2026 results. Lazard reported adjusted EPS of $0.36, below estimates, and revenue of $805M, up 11% YoY but below expectations. Shares have fallen 21% YTD. Goldman Sachs raised its price target to $35 but kept a Sell rating, citing expense management. Lazard's dividend yield is 5.36%.

$LAZMed

Lazard Inc (LAZ) (Q3 2026) Earnings Call Highlights: Record Advisory Revenue

Lazard Inc (LAZ) reported Q3 2026 earnings with record advisory revenue but faced asset management outflows of $2.3B. CEO Peter Orszag highlighted growth opportunities from the Campbell Lutzens acquisition and strong advisory pipeline. CFO Tracy Farr discussed compensation ratio management. Management acknowledged macroeconomic challenges and potential M&A delays due to higher interest rates.

$LAZLow

Goldman Sachs raises Lazard stock price target on expense management

Goldman Sachs raised its price target for Lazard (NYSE:LAZ) to $35 from $32, maintaining a Sell rating. Lazard's Q3 2026 adjusted EPS of $0.36 missed estimates, with revenue 6% below expectations. Despite this, the company expects strong Financial Advisory performance and positive net organic flows in asset management. Goldman reduced its earnings estimates for 2026-2028 but increased its target P/E multiple.

$LAZMed

What Lazard (LAZ) Said on Its Q3 Earnings Call

Lazard (LAZ) reported strong Q3 results, with advisory revenue split 61% M&A and 39% non-M&A. Conflict clearances rose 30%+ YoY, and its 2027 pipeline is twice 2026's. Asset management fees hit a record $321M, up 18% YoY, with AUM at $284B. Management expects H2 2026 to outperform H1, driven by strategic transactions and restructuring activity. The company returned $88M to shareholders and plans efficiency initiatives.

$LAZHighAI 8/10

Lazard (LAZ) Q3 2026 Earnings Call Transcript

Lazard (LAZ) reported Q3 2026 earnings, highlighting 11% year-over-year revenue growth. The firm plans to close its acquisition of Campbell Lutyens, launching Lazard CL, expected to generate $500M in 2027 revenue. Financial advisory saw record revenue, with strong forward indicators and pipeline growth. Asset management reported record gross inflows of $54B for the first nine months.